Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
Novel human Siglec-7 monoclonal and bispecific antibodies are being developed as potential future cancer immunotherapies